Vanda Pharmaceuticals Inc. VNDA
3.88 USD +0.13 (+3.47%)
At closeNov 5, 2026, 6:21 AM EST
3.83 -0.05 -1.30%
Pre-market · Nov 5, 6:21 AM ET
3.73 Day range 3.91
3.64 52-week range 9.94
- YTD
- -56.01%
- 1 year
- -10.80%
News
prnewswire.com Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences WASHINGTON, Nov. 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in November…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
benzinga.com Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer Reed Jobs says GLP-1 drugs could help fight cancer; Yosemite fund passes $350M target.
benzinga.com Vanda Pharma Q3 2026 Earnings Call Transcript Vanda Pharma (NASDAQ:VNDA) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time…
benzinga.com Vanda Pharma Q3 EPS $(0.37) Beats $(0.68) Estimate, Sales $69.815M Beat $69.202M Estimate Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.68) by 45.59 percent. This is a 2.63 percent increase over losses of $(0.38)…
benzinga.com Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes Vanda Pharmaceuticals reports positive Phase 3 results for Nereus, demonstrating reduced vomiting linked to GLP-1 receptor agonist therapy.
benzinga.com Vanda Pharmaceuticals Announces Phase III Study Results Showing Significant Reduction In GLP-1 Therapy-Associated Vomiting With NEREUS NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomitingKey ResultsAny vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27%…
benzinga.com Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint Vanda Pharmaceuticals announced its Phase 3 trial for VQW-765 failed to meet primary endpoints for treating acute social anxiety disorder.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap…- benzinga.com Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpointConsistent with prior studies, VQW-765 was safe and well toleratedWASHINGTON, Oct. 14, 2026…
benzinga.com HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and maintains $20 price target.